Medical Patent News

RSS

Celsis IVT files patent infringement lawsuit against Invitrogen, CellzDirect

Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against Invitrogen Corporation and CellzDirect, Inc. in the United States District Court for the Northern District of Illinois in Chicago and has moved for a preliminary injunction. Invitrogen, the parent of CellzDirect, is itself a wholly-owned subsidiary of Life Technologies of Carlsbad, California.

1 Jul 2010

PIKAMAB secures exclusive rights to issued U.S. patent from UABRF

PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has secured exclusive rights to an issued U.S. patent (US 6,986,987) from the UAB Research Foundation. This patent pertains to the discovery that the functional polymorphism (Ser/Gly248) in the cytoplasmic domain of Fc alpha receptor determines the proinflammatory potential of serum IgA autoantibodies through cell signaling and production of cytokines such as TNF-alpha, IL-6, and IL-1β in an allele-dependent manner.

1 Jul 2010

Biospherics acquires worldwide patent rights to Dtagatose from UKRF

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome, and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its wholly-owned subsidiary, Biospherics Incorporated, has signed a license agreement with the University of Kentucky Research Foundation (UKRF).

1 Jul 2010

USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody

Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.

1 Jul 2010

US District Court upholds validity and enforceability of CRESTOR patent

AstraZeneca announced today that Judge Joseph Farnan, Jr., US District Court, District of Delaware, has found that the substance patent protecting CRESTOR (RE37,314 – the '314 patent) is valid and enforceable. In its ruling, the court found that no inequitable conduct was committed by any Shionogi employee. The court also held the '314 patent to be non-obvious and properly reissued.

30 Jun 2010

USPTO grants Vermillion Alzheimer's disease biomarker patent

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Biomarkers for Alzheimer's disease" to the Company.

29 Jun 2010

Corgenix Medical issued additional U.S. patent covering AspirinWorks technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks technology and product line.

25 Jun 2010

Patent application for tumor specific NPC-1C Antigen filed by Neogenix Oncology

Neogenix Oncology announced today that it has filed a patent application with the US Patent and Trade Office for the NPC-1C antigen. This antigen appears to be tumor specific for pancreatic and colorectal tumors.

24 Jun 2010

USPTO grants Tethys key patent for PreDx Diabetes Risk Score test

Tethys Bioscience, Inc., a privately held company, announced today that the United States Patent and Trademark Office has granted the Company US Patent 7,723,050. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.

24 Jun 2010

International Stem Cell congratulates ACT on the issuance of its recent patent

International Stem Cell Corporation, www.intlstemcell.com, a California-based biotechnology company focused on therapeutic and research products, congratulates Advanced Cell Technology, Inc. on the issuance of its recent patent, U.S. Patent Number 7,736,896, covering a method for producing retinal pigment epithelial cells.

24 Jun 2010

USPTO confirms validity of DUSA's key Levulan PDT patent

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid."

24 Jun 2010

AGA refused permission to appeal UK Supreme Court for Figulla ASD and PFO occluder patent infringement

In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.

24 Jun 2010

USPTO rules against claims in LifeWatch '878 patent

Medicomp, Inc. confirmed that it has received an initial ruling by the United States Patent and Trademark Office (USPTO) to reject all claims in regards to LifeWatch patent 7,542,878 (the '878 patent).

24 Jun 2010

UK court finds Smith & Nephew's Renasys EZ and Go products infringe KCI patents

Kinetic Concepts, Inc. today announced that the High Court of Justice Chancery Division, Patents Court in the United Kingdom has found that Smith & Nephew plc's Renasys EZ and Go products infringe two KCI patents relating to negative pressure wound therapy.

24 Jun 2010

Aphios awarded US patent for process to formulate polymeric microspheres, nanospheres

Aphios Corporation today announced that it was awarded United States Patent No. 7,708,915 B2 for "Polymer Microspheres/Nanospheres and Encapsulating Therapeutic Proteins Therein," granted May 04, 2010. This invention is an improved process to formulate polymeric microspheres and nanospheres, and encapsulate therapeutic proteins or other useful substances, and a polymer microspheres/nanospheres apparatus.

24 Jun 2010

K-State chemical engineer patents chemical structure to make natural personal care products in lab

A Kansas State University chemical engineer has developed and patented a chemical structure to make all-natural personal care products and purer pharmaceuticals in the laboratory.

23 Jun 2010

Corgenix receives new European patent for AtherOx technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, announced today the issuance of one new European patent for the company's AtherOx® (oxLDL/B2GPI) technology and the publication of an important clinical trial studying oxLDL/B2GPI levels in patients with acute coronary syndrome (ACS).

23 Jun 2010

USPTO issues patent related to Derma Sciences' MEDIHONEY Calcium Alginate Dressing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that the U.S. Patent and Trademark Office has issued patent No. 7,714,183 related to the Company's MEDIHONEY Calcium Alginate Dressing.

22 Jun 2010

Sun Pharma settles litigation with Orion over generic Stalevo, Comtan ANDAs

Sun Pharmaceutical Industries Ltd. announced that together with its affiliates ("Sun Pharma") it has executed a settlement agreement with Orion stipulating a dismissal of the lawsuits filed in the United States against Sun Pharma regarding submission of Abbreviated New Drug Applications (ANDAs) for generic versions of Stalevo® and Comtan® tablets.

22 Jun 2010

Biodesix awarded US patent for VeriStrat serum test

Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy.

22 Jun 2010